Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

NBIXBearishCorporate Developmentsnews

High materiality8/10

Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance

Feb 12, 2026, 2:56 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The earnings miss reflects potential operational inefficiencies and could prompt bearish sentiment, similar to historical instances where companies with minor earnings declines faced heightened scrutiny and stock price drops.

AI summary

What happened, with direct paths to the underlying reporting

Neurocrine Biosciences reported fourth-quarter adjusted earnings of $1.88, slightly below analysts' expectations of $1.89. This small miss may signal potential challenges in revenue growth and market performance, which could trigger investor caution in the near term.

NBIX Q4 earnings miss consensus by $0.01 at $1.88 per share.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.